Anita W. Rijneveld
YOU?
Author Swipe
View article: The Right Glucarpidose?
The Right Glucarpidose? Open
View article: Metabolomics in sickle cell disease: Current knowledge and gaps – A scoping review
Metabolomics in sickle cell disease: Current knowledge and gaps – A scoping review Open
Sickle cell disease (SCD) has large phenotypic variability. Systematic metabolomic profiling may provide insights into phenotypes and treatment responses. We conducted a scoping review on associations between blood metabolites, SCD-related…
View article: Iron Deficiency in HbSC Disease Treated With Repetitive Phlebotomy Is Associated With Fewer Sickle Cell Disease‐Related Complications
Iron Deficiency in HbSC Disease Treated With Repetitive Phlebotomy Is Associated With Fewer Sickle Cell Disease‐Related Complications Open
View article: Transcriptional profiling directs the classification of acute leukemias of ambiguous lineage into AML, B‐ALL, or T‐ALL
Transcriptional profiling directs the classification of acute leukemias of ambiguous lineage into AML, B‐ALL, or T‐ALL Open
Acute leukemia of ambiguous lineage (ALAL) is a rare, poor‐prognosis acute leukemia subtype that cannot be assigned to a single hematopoietic lineage. Although ALAL patients are typically treated with acute myeloid leukemia (AML) or acute …
View article: Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies
Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies Open
Relapsed/refractory T-cell acute lymphoblastic leukemia (ALL; T-ALL)/lymphoma (LBL) represent a significant unmet medical need. WU-CART-007 is a CD7-targeting, allogeneic, fratricide-resistant chimeric antigen receptor T-cell product gener…
View article: COVID- 19 in patients affected by red blood cell disorders, results from the European registry ERN-EuroBloodNet
COVID- 19 in patients affected by red blood cell disorders, results from the European registry ERN-EuroBloodNet Open
View article: The use of race and ethnicity in sickle cell disease research
The use of race and ethnicity in sickle cell disease research Open
This study explores practices surrounding the operationalization of ethno-racial categories (ERCs) as confounders in biomedical research, with a focus on sickle cell disease (SCD) as a model. ERCs, often aggregate labels encompassing diver…
View article: Pyruvate Kinase Function Correlates With Red Blood Cell Properties and Clinical Manifestations in Sickle Cell Disease
Pyruvate Kinase Function Correlates With Red Blood Cell Properties and Clinical Manifestations in Sickle Cell Disease Open
Pyruvate kinase (PK) is a key enzyme involved in the final step of glycolysis, essential to produce adenosine triphosphate (ATP). Relatively decreased red blood cell (RBC) PK activity (reflected by a lower PK/hexokinase [HK] ratio) and PK …
View article: Red blood cell pyruvate kinase properties in Townes and Berkeley sickle cell disease mouse models – Of mice and men
Red blood cell pyruvate kinase properties in Townes and Berkeley sickle cell disease mouse models – Of mice and men Open
Pyruvate kinase (PK), a key ATP-generating enzyme in glycolysis, is a target for novel sickle cell disease (SCD) therapies. Enhancing PK activity lowers 2,3-diphosphyglycerate (2,3-DPG), increases adenosine triphosphate (ATP), and may prev…
View article: Oxidantscan: a novel biomarker to assess red blood cell susceptibility to oxidative stress in sickle cell disease
Oxidantscan: a novel biomarker to assess red blood cell susceptibility to oxidative stress in sickle cell disease Open
View article: Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab
Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab Open
This narrative review seeks to summarize chemotherapeutic regimens commonly used for patients with newly diagnosed Philadelphia (Ph) chromosome-negative B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in the frontline setting and t…
View article: COVID-19 in patients affected by red blood cell disorders, results from the European registry ERN-EuroBloodNet
COVID-19 in patients affected by red blood cell disorders, results from the European registry ERN-EuroBloodNet Open
Background Despite several publications covering patients from multiple centers, no international registry covered all patients with red blood cell diseases (RBCD) affected by COVID-19. The ERN-EuroBloodNet's registry provided real-time re…
View article: Anti-CD7 allogeneic WU-CART-007 in patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma: a phase 1/2 trial
Anti-CD7 allogeneic WU-CART-007 in patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma: a phase 1/2 trial Open
View article: Epigenetic alterations affecting hematopoietic regulatory networks as drivers of mixed myeloid/lymphoid leukemia
Epigenetic alterations affecting hematopoietic regulatory networks as drivers of mixed myeloid/lymphoid leukemia Open
View article: Phase 1 Study of the Safety and Pharmacokinetics of CSL889 (Hemopexin) in Adults with SCD
Phase 1 Study of the Safety and Pharmacokinetics of CSL889 (Hemopexin) in Adults with SCD Open
Presentation Date: 6/8/2024 Presentation Start Time: 9:00:00 AM Background Vaso-occlusive crisis (VOC) is the primary reason for hospitalization among patients with sickle cell disease (SCD). Free heme from ongoing hemolysis contributes to…
View article: Metabolic blood profile and response to treatment with the pyruvate kinase activator mitapivat in patients with sickle cell disease
Metabolic blood profile and response to treatment with the pyruvate kinase activator mitapivat in patients with sickle cell disease Open
Mitapivat is an investigational, oral, small‐molecule allosteric activator of pyruvate kinase (PK). PK is a regulatory glycolytic enzyme that is key in providing the red blood cell (RBC) with sufficient amounts of adenosine triphosphate (A…
View article: Results from UKALL60+, a phase 2 study in older patients with untreated acute lymphoblastic leukemia
Results from UKALL60+, a phase 2 study in older patients with untreated acute lymphoblastic leukemia Open
Poor outcome for older patients with ALL has multiple attributions, including a higher incidence of high-risk genetic features,1 and comorbidities as well as treatment intolerance.2, 3 The phase 2 clinical trial UKALL60+ (NCT01616238) was …
View article: Benefits and risks of clofarabine in adult acute lymphoblastic leukemia investigated in depth by multi‐state modeling
Benefits and risks of clofarabine in adult acute lymphoblastic leukemia investigated in depth by multi‐state modeling Open
Background We recently reported results of the prospective, open‐label HOVON‐100 trial in 334 adult patients with acute lymphoblastic leukemia (ALL) randomized to first‐line treatment with or without clofarabine (CLO). No improvement of ev…
View article: Tyrosine kinase inhibitor resistance in de novo <i>BCR</i>::<i>ABL1</i>–positive BCP-ALL beyond kinase domain mutations
Tyrosine kinase inhibitor resistance in de novo <i>BCR</i>::<i>ABL1</i>–positive BCP-ALL beyond kinase domain mutations Open
A better understanding of ABL1 kinase domain mutation–independent causes of tyrosine kinase inhibitor (TKI) resistance is needed for BCR::ABL1–positive B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Although TKIs have dramaticall…
View article: Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia
Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia Open
Blinatumomab is a BiTE® (bispecific T‐cell engager) molecule that redirects CD3 + T‐cells to engage and lyse CD19 + target cells. Here we demonstrate that subcutaneous (SC) blinatumomab can provide high efficacy and greater convenience of …
View article: Management of ALL in adults: 2024 ELN recommendations from a European expert panel
Management of ALL in adults: 2024 ELN recommendations from a European expert panel Open
Experts from the European Leukemia Net (ELN) working group for adult acute lymphoblastic leukemia have identified an unmet need for guidance regarding management of adult acute lymphoblastic leukemia (ALL) from diagnosis to aftercare. The …
View article: Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel
Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel Open
Working groups of the European LeukemiaNet have published several important consensus guidelines. Acute lymphoblastic leukemia (ALL) has many different clinical and biological subgroups and the knowledge on disease biology and therapeutic …
View article: Oxygen gradient ektacytometry–derived biomarkers are associated with acute complications in sickle cell disease
Oxygen gradient ektacytometry–derived biomarkers are associated with acute complications in sickle cell disease Open
We investigated the potential of the point of sickling (PoS; the pO2 tension at which red cells start to sickle), determined by oxygen gradient ektacytometry to serve as a biomarker associated with the incidence of acute sickle cell diseas…
View article: One-year safety and efficacy of mitapivat in sickle cell disease: follow-up results of a phase 2, open-label study
One-year safety and efficacy of mitapivat in sickle cell disease: follow-up results of a phase 2, open-label study Open
Targeting the primary pathogenic event of sickle cell disease (SCD), the polymerization of sickle hemoglobin (HbS), may prevent downstream clinical events. Mitapivat, an oral pyruvate kinase (PK) activator, has therapeutic potential by inc…
View article: PB0939 Effect of Pegylated Asparaginase on Coagulation Parameters and Thrombin Generation in Adults with Acute Lymphoblastic Leukemia
PB0939 Effect of Pegylated Asparaginase on Coagulation Parameters and Thrombin Generation in Adults with Acute Lymphoblastic Leukemia Open
small retrospective studies suggest that DOAC may be associated with a lower risk of intracranial hemorrhage (ICH) than LMWH in this patient population.Aims: To perform a meta-analysis of all studies comparing DOAC with LMWH in patients wi…
View article: Real-world evaluation of UK high hyperdiploidy profile using a large cohort of patients provided by HARMONY data platform
Real-world evaluation of UK high hyperdiploidy profile using a large cohort of patients provided by HARMONY data platform Open
View article: P361: HIGH REMISSION AND SURVIVAL RATE IN ADULTS WITH MINIMAL RESIDUAL DISEASE-POSITIVE OR RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA TREATED WITH BLINATUMOMAB IN ROUTINE CLINICAL PRACTICE
P361: HIGH REMISSION AND SURVIVAL RATE IN ADULTS WITH MINIMAL RESIDUAL DISEASE-POSITIVE OR RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA TREATED WITH BLINATUMOMAB IN ROUTINE CLINICAL PRACTICE Open
Background: This prospective observational study included adult patients (pts) who received blinatumomab for treatment of minimal residual disease-positive (MRD+) or relapsed/refractory (R/R) Philadelphia chromosome-negative (Ph-) B-cell A…
View article: P1424: ONE-YEAR FOLLOW-UP OF A PHASE 2 STUDY OF MITAPIVAT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR THE TREATMENT OF SICKLE CELL DISEASE
P1424: ONE-YEAR FOLLOW-UP OF A PHASE 2 STUDY OF MITAPIVAT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR THE TREATMENT OF SICKLE CELL DISEASE Open
Topic: 26. Sickle cell disease Background: Sickle cell disease (SCD) is a hereditary red blood cell (RBC) disorder characterized by a defective hemoglobin (HbS), which polymerizes upon deoxygenation. The poorly deformable, sickled RBCs cau…
View article: Allogeneic Stem Cell Transplantation in Patients >40 Years of Age With Acute Lymphoblastic Leukemia: Reduced Intensity Versus Myeloablative Conditioning
Allogeneic Stem Cell Transplantation in Patients >40 Years of Age With Acute Lymphoblastic Leukemia: Reduced Intensity Versus Myeloablative Conditioning Open
Background. The outcome in older patients with acute lymphoblastic leukemia (ALL) remains unsatisfactory due to high relapse and nonrelapse mortality (NRM) rates. Allogeneic stem cell transplantation (alloHSCT) as postremission therapy has…
View article: PI-04: OXYGEN GRADIENT EKTACYTOMETRY-DERIVED BIOMARKERS ARE ASSOCIATED WITH THE OCCURRENCE OF ACUTE COMPLICATIONS IN SICKLE CELL DISEASE
PI-04: OXYGEN GRADIENT EKTACYTOMETRY-DERIVED BIOMARKERS ARE ASSOCIATED WITH THE OCCURRENCE OF ACUTE COMPLICATIONS IN SICKLE CELL DISEASE Open
Purpose: Sickle cell disease (SCD) is a monogenetic disorder with a highly complex pathophysiology. There is an unmet need for robust reproducible biomarkers that can assess red blood cell (RBC) function and predict disease severity and co…